FDA clears RxSight’s light-adjustable intraocular lens for implants

FDA clears RxSight's intraocular light adjustable lens for cataract surgery.

The FDA gave its okay to RxSight’s implantable, light-adjustable intraocular lens that can make small adjustments that provide better vision for cataract surgery patients when they aren’t using glasses. 

The device uses a UV light reactive material that is treated by a specific Light Delivery Device over the course of one to two weeks (usually three to four light treatments) after cataract surgery is performed. The patient wears special eyeglasses for UV protection from the time of the cataract surgery until the light treatments are completed to protect the new lens from UV light in the environment.

“Until now, refractive errors that are common following cataract surgery could only be corrected with glasses, contact lenses or refractive surgery,” Malvina Eydelman, M.D., director of the Division of Ophthalmic, and Ear, Nose and Throat at the FDA’s Center for Devices and Radiological Health, said in a statement. “This system provides a new option for certain patients that allows the physician to make small adjustments to the implanted lens during several in-office procedures after the initial surgery to improve visual acuity without glasses.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The regulatory agency clearance was granted based on a 600-patient clinical study that evaluated the safety and effectiveness of the RxSight Light Adjustable Lens and Light Delivery Device. On average, six months after the procedure patients reported an improvement of about one additional line down the vision chart for distance vision without glasses, compared to a conventional IOL. Six months after surgery, 75% experienced a reduction in astigmatism.

The device is intended for patients who have astigmatism within the cornea before surgery and who do not have macular diseases.

Suggested Articles

The FDA has cleared its first duodenoscope designed to make the intricate, moving and difficult-to-clean parts in the head of the device disposable.

The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12.

Novartis tapped Biofourmis to develop tracking programs for heart failure patients, as the latter acquired Biovotion, makers of clinical wearables.